TRIP12 anticorps (AA 1-240)

N° du produit ABIN7151292

Détail du produit anti-TRIP12 anticorps

Antigène: TRIP12 (Thyroid Hormone Receptor Interactor 12 (TRIP12))

Épitope: AA 1-240

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TRIP12 est non-conjugé

Application: Immunohistochemistry (IHC), ELISA

Réactivité croisée: Humain

Purification: Antigen Affinity Purified

Immunogène: Recombinant Human E3 ubiquitin-protein ligase TRIP12 protein (1-240AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: IHC:1:20-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur TRIP12

Antigène: TRIP12 (Thyroid Hormone Receptor Interactor 12 (TRIP12))

Autre désignation: TRIP12 (TRIP12 Produits)

Synonymes: anticorps ULF, anticorps TRIP-12, anticorps 1110036I07Rik, anticorps 6720416K24Rik, anticorps AA410158, anticorps Gtl6, anticorps thyroid hormone receptor interactor 12, anticorps E3 ubiquitin-protein ligase TRIP12, anticorps TRIP12, anticorps CpipJ_CPIJ012812, anticorps PTRG_06487, anticorps LOAG_11488, anticorps LOC100631469, anticorps Trip12

Sujet:

Background: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardeless of the presence of lysine residues in target proteins. In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress. In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation. Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation. Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins. Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of \\\'Lys-63\\\'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes.

Aliases: TRIP12 antibody, KIAA0045 antibody, ULF antibody, E3 ubiquitin-protein ligase TRIP12 antibody, EC 2.3.2.26 antibody, E3 ubiquitin-protein ligase for Arf antibody, ULF antibody, HECT-type E3 ubiquitin transferase TRIP12 antibody, Thyroid receptor-interacting protein 12 antibody, TR-interacting protein 12 antibody, TRIP-12 antibody

UniProt: Q14669

Pathways: Nuclear Hormone Receptor Binding